RGD Reference Report - Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds.

Authors: Hayden, F G  Gwaltney, J M 
Citation: Hayden FG and Gwaltney JM, J Infect Dis. 1984 Aug;150(2):174-80. doi: 10.1093/infdis/150.2.174.
RGD ID: 40886344
Pubmed: PMID:6381610   (View Abstract at PubMed)
DOI: DOI:10.1093/infdis/150.2.174   (Journal Full-text)

The therapeutic efficacy of recombinant interferon-alpha 2 (HuIFN-alpha 2) in experimental infection with rhinovirus type 39 was assessed in two randomized, double-blind, placebo-controlled studies. Adult volunteers (serum neutralizing antibody titer, less than or equal to 1:2) were given 9 X 10(6) international units of HuIFN-alpha 2 three times a day for five days by intranasal spray (study 1) or drops (study 2) beginning 28 hr after rhinovirus inoculation. HuIFN-alpha 2 did not prevent rhinovirus infection or colds in either study. Treatment by nasal drops and to a lesser extent by spray was associated with significant reductions in duration and quantity of viral shedding. Treatment by drops was associated with significant but modest effects on nasal symptom scores and trends toward reduced quantities of production of nasal mucus. Despite lower nasal wash concentrations of interferon, HuIFN-alpha 2 drops appeared to have greater antiviral activity and therapeutic efficacy than did HuIFN-alpha 2 spray. These findings suggest that HuIFN-alpha 2 may not be therapeutically useful in treating naturally occurring rhinoviral colds.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
common cold treatmentIDA 40886344 RGD 
common cold treatmentISO 40886344; 40886344 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Ifna2  (interferon alpha 2)

Genes (Mus musculus)
Ifna2  (interferon alpha 2)

Genes (Homo sapiens)
IFNA2  (interferon alpha 2)


Additional Information